Phase II Clinical Trial of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer With Correlative Assessment of Hormone Intermediates.
Latest Information Update: 13 Jun 2024
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 29 May 2024 Planned End Date changed from 1 Apr 2024 to 1 Jun 2024.
- 01 Mar 2024 Planned End Date changed from 1 Jan 2024 to 1 Apr 2024.
- 07 Dec 2023 Planned End Date changed from 1 Nov 2023 to 1 Jan 2024.